"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial of olaparib with chemotherapy for advanced ovarian cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at having a drug called olaparib at the same time as chemotherapy. It is for women with the most common type of ovarian cancer (serous type epithelial ovarian cancer) that has come back after treatment.
If ovarian cancer comes back after chemotherapy, you may have more chemotherapy. If your cancer responded to a platinum drug the first time you had treatment, you may have a platinum drug again. This trial is for women who have ovarian cancer that responded to a platinum drug before. Some of the women taking part will also have a drug called olaparib.
Olaparib (also known as AZD2281) is a type of biological therapy called a PARP inhibitor.
Every cell contains DNA. This is the genetic information that controls how cells behave. If DNA becomes damaged (as in cancer cells), a protein called PARP-1 helps to repair it. Olaparib stops PARP-1 from working. If PARP-1 doesn’t work, cancer cells can’t repair themselves and they die.
The aims of the trial are to
- See if a combination of olaparib and chemotherapy works better than chemotherapy alone for women with advanced ovarian cancer
- Learn more about the side effects of having olaparib and chemotherapy together
Who can enter
You can enter this trial if you
- Have ovarian, primary peritoneal or fallopian tube cancer that is at least partly serous type
- Have cancer that didn’t start to grow again for at least 6 months after your last chemotherapy with a
- Have at least one area of cancer that doctors can see and measure on a scan
- Have satisfactory blood test results
- Are well enough to be up and about for at least half the day (performance status 0, 1 or 2)
- Have been through the
menopauseand haven’t had periods for at least a year, or you have had your ovaries or womb removed
- Are at least 18 years old
You cannot enter this trial if you
- Have cancer that has spread to your brain and is causing symptoms despite treatment
- Have already had more than 3 different types of chemotherapy
- Have had chemotherapy or radiotherapy in the last 2 weeks, apart from radiotherapy to treat symptoms
- Have started taking drugs called bisphosphonates in the last 4 weeks
- Have had major surgery in the last 2 weeks, or have not recovered from earlier surgery
- Have not recovered from the side effects of other treatment, unless they are very mild
- Have had an experimental drug as part of another clinical trial in the last 2 weeks
- Have had another cancer in the last 5 years apart from non melanoma skin cancer or carcinoma in situ of the cervix that has been treated, ductal carcinoma in situ (DCIS) or womb cancer that was stage 1 and grade 1
- Have already had a PARP inhibitor drug
- Have had an allergic reaction to carboplatin or another platinum drug
- Are known to be sensitive to paclitaxel or olaparib, or anything in them
- Are taking certain drugs that can affect how an enzyme called CYP3A4 works (your doctor will advise you about this)
- Have fits (seizures) that cannot be controlled with medication
- Have another serious medical condition that cannot be controlled with medication
- Are known to be HIV, hepatitis B or hepatitis C positive or have low immunity
- Cannot swallow or absorb tablets for any reason
- Are breastfeeding
This phase 2 trial will recruit about 150 women in a number of different countries. It is a randomised trial. You will be put into 1 of 2 treatment groups by a computer. Neither you nor your doctor can decide which group you are in.
If you are in group A, you have carboplatin and paclitaxel chemotherapy through a drip into a vein. This takes about 4 hours. You have this treatment every 3 weeks and each 3 week period is called a cycle of treatment. You have 6 cycles all together. You also take 4 olaparib capsules twice a day on the first 10 days of each treatment cycle.
After finishing 6 cycles of chemotherapy, you may carry on taking olaparib until your cancer starts to grow again.
If you are in group B, you have chemotherapy in the same way, but you have a higher dose of carboplatin. You don’t take olaparib capsules, and you finish treatment as part of the trial after the 6 cycles of chemotherapy.
You will see the doctors and have some tests before you start treatment. The tests include
During the first 2 cycles of treatment, you go to hospital once a week. On the first day you see the doctors, have blood tests and chemotherapy. On the other days you just have a physical examination and blood tests.
For the next 4 cycles of treatment, you go to hospital on the first day only. You see the doctors, have blood tests and the chemotherapy. You have a CT or MRI scan at the end of cycle 3.
At the end of the last cycle of chemotherapy, you see the trial doctors, have more blood tests and an ECG. If you are in group A, you can carry on taking olaparib after you finish chemotherapy, as long as you have had more than 4 cycles of treatment. People in group A will have weekly visits for the first three weeks after they stop chemotherapy.
Everybody will see the trial doctors again 6 weeks later, and have another scan. You then have follow up appointments every 6 weeks, with scans every 3 months until your cancer starts to grow again. After this, the trial team will contact you every 3 months.
The side effects of carboplatin, paclitaxel and olaparib include
- A drop in blood cells causing an increased risk of infection, tiredness, shortness of breath and bruising or bleeding problems
- Feeling or being sick
- Tiredness (fatigue)
- Inflammation of the lungs
There is more information about other possible side effects of carboplatin and paclitaxel on CancerHelp UK.
How to join a clinical trial
Professor Chris Poole
Experimental Cancer Medicine Centre (ECMC)